US REGULATORY RECORDS
- FDA API DMF records
- 41
- Active (A)
- 28
- Inactive (I)
- 13
FDA list cutoff:
ACTIVE PHARMACEUTICAL INGREDIENT
Research Omeprazole API through FDA DMF and China CDE records. Compare reported holders, registration numbers and status definitions, then subscribe to search and export complete available data.
Complete data requires an active subscription. Already subscribed? Sign in to access your data.
This profile covers racemic Omeprazole in its free form, CAS 73590-58-6. Sodium and magnesium salts, Esomeprazole, finished dosage forms, pellets and intermediates are excluded. A reported name does not verify the composition, crystalline form or specification of a supplied batch.
This overview includes 41 FDA API DMF records and 18 CDE API registrations for Omeprazole (CAS 73590-58-6), selected by reported substance name. FDA and CDE status counts follow each registry’s own definitions.
FDA list cutoff:
CDE export captured:
0 documented company-name correspondences
The registries have different snapshot dates. Record counts do not represent qualified or available suppliers. Omeprazole subjects are selected by reported name, not by an independently verified CAS assignment for every filing. A lack of documented company-name correspondences does not establish that no companies appear in both registries.
$19.00 per month
$149.00 per year
Billed $149.00 every year
This profile: 41 FDA DMF records, 18 CDE registrations and 0 company-name correspondences.
One personal account can access subscription datasets currently available on APIRFQ. Coverage varies by product. This does not include quotations, supplier qualification or live monitoring.
Start an Omeprazole supplier search with the reported names in each market. No cross-registry company-name correspondences are documented for this profile. Similar names, translations and membership of the same corporate group do not prove an identical legal entity or manufacturing site.
Free previewShowing 0 sample records of 0.
0 company-name correspondences
No exact company-name correspondences are documented for these snapshots.
Other records remain available below and in the registry tables. A missing name correspondence does not imply a missing registration.
Original reported names are preserved. A CDE company field may contain several named parties; their roles are not inferred from name order. Unmatched names are not treated as ineligible suppliers.
US REGULATORY RECORDS
Compare Omeprazole holder names, original subjects, submission dates and activity status. Sieved, process-qualified and Form B subjects remain distinct records; those descriptions do not verify the specification of a supplied batch.
28Active (A)
13Inactive (I)
A = active; I = inactive. DMFs are neither approved nor disapproved by FDA. These entries do not establish supplier qualification, manufacturing-site approval, dossier access or current availability.
Free previewShowing 3 sample records of 41.
Free preview
More records available with a subscription: 38.
CHINA REGULATORY RECORDS
Compare Omeprazole registrations by number, reported company, product origin and Chinese review status. The table preserves original Chinese substance names and company fields for verification against the official registry.
13Approved or qualifying prior approval (A)
5Technical review not passed or unlinked (I)
CDE A and I describe Chinese review status independently of FDA activity. A can follow joint review, transfer of qualifying prior approvals or independent API review. I means technical review has not been passed or the material has not been linked to a formulation registration. Reported validity dates and status do not independently establish current supplier qualification.
Free previewShowing 3 sample records of 18.
Free preview
More records available with a subscription: 15.
Omeprazole is a proton pump inhibitor. ChEBI defines it as a racemate containing equal amounts of the R and S enantiomers, with CAS 73590-58-6. This profile identifies the free form. Esomeprazole is the S enantiomer; sodium and magnesium salts are separate chemical forms. The registry lists do not individually verify these chemical identifiers for every entry.
Reference identity of the racemic free form; not a CAS assignment independently verified for each registration.
Use these molecular properties when checking the free-form identity. Omeprazole salts have different compositions, and an enantiomer can share the same formula and mass without being the same substance. Confirm chemical form, crystalline form, assay basis and specification with the manufacturer; identifiers alone do not establish interchangeability.
Reference molecular weight of the free form; not a batch assay or purity result.
Check Omeprazole identity, structural information and registration scope in these original references.
Confirm the Omeprazole racemate and CAS 73590-58-6 before comparing registration names.
View the official Omeprazole molecular structure, formula and reference masses.
Understand why an active DMF does not mean approval of a product or supplier.
Check current Omeprazole entries and their reported companies, packaging and review information.
This profile covers Omeprazole, CAS 73590-58-6, in its racemic free form. Its molecular formula is C17H19N3O3S and reference molecular weight is 345.42 g/mol. Registration tables are selected by reported substance name; the source lists do not independently establish CAS identity, crystalline form or batch specifications for every record.
No. Omeprazole is a racemate of the R and S enantiomers; Esomeprazole identifies the S enantiomer. Sodium and magnesium salts are distinct chemical forms. Their registrations are excluded from this free-form profile. Do not use a shared name fragment, molecular mass or therapeutic category as evidence that materials are interchangeable.
The FDA snapshot includes 41 Type II Omeprazole API records with unqualified, USP, active drug substance, non-sterile drug substance, sieved, process-qualified or Form B subjects. The original qualifiers remain visible. Type II also covers intermediates and drug products, so type alone is insufficient to identify an API filing.
Form B describes a crystalline form of Omeprazole in the published application US20100183710A1. The three Form B subjects are retained with their exact wording; this does not verify a particular batch’s solid-state properties. Pellets, capsules and tablets describe formulated materials or dosage forms and are outside this API profile. The chloro compound and sulphide subjects are also excluded as related intermediate candidates.
No. FDA A and I indicate active and inactive DMFs. FDA states that DMFs are neither approved nor disapproved and reviews their technical contents with applications that reference them. An Omeprazole DMF listing does not prove manufacturing-site qualification, a right to reference a dossier, current supply or suitability for a specific application.
The CDE selection contains 18 records named exactly 奥美拉唑. Registrations for 奥美拉唑钠 and 奥美拉唑镁 are separate salt forms; 艾司奥美拉唑 entries are excluded as a different enantiomeric identity. All eleven original columns are retained, including blank values, multiple company names, addresses, packaging, dates and approval references.
For Omeprazole registrations, CDE A and I describe Chinese review status independently of FDA activity. A can follow review with an approved formulation, transfer of qualifying prior approvals or an independent API review. I identifies material that has not passed technical review or has not been linked to a formulation registration. Check the current official entry before relying on its status.
Use the registry number to locate the official entry, then ask the company to confirm its legal identity, manufacturing site, chemical and crystalline form, specification and relevant regulatory documentation. Omeprazole supplier qualification also requires a separate quality assessment. A CDE company field may name multiple parties; their order does not establish their roles or a match to an FDA holder.
Review free Omeprazole samples and download their sample CSV files before subscribing. An active personal subscription provides the complete available records for this profile, with search, status filters and CSV exports. It does not include quotations, supplier qualification or live registry monitoring. Snapshot dates remain visible so you can distinguish the records from a current official lookup.
Primary references for chemical identity, registration records and status definitions. Open each source to check its scope and current information.
EMBL-EBI
Chemical definition, racemic identity and CAS number of the Omeprazole free form.
“A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.”
EMBL-EBI
ChEBI definition of CHEBI:7772; the entry also reports CAS 73590-58-6.
KEGG
Molecular formula, molecular weight, exact mass, structure and drug classification for the free form.
“C17H19N3O3S”
KEGG
Molecular formula reported in KEGG Drug entry D00455; the same entry reports molecular weight 345.42 and exact mass 345.1147.
EMBL-EBI
Defines Esomeprazole by its S configuration and distinguishes it from the Omeprazole racemate.
“(S)-omeprazole”
EMBL-EBI
Synonym in ChEBI CHEBI:50275; the definition specifies S configuration at the sulfur atom.
U.S. patent application US20100183710A1
The published application describes crystalline Form B of Omeprazole. It supports interpreting the Form B qualifier, not any listed holder’s batch characteristics, patent rights or freedom to operate.
“crystalline Form B of omeprazole”
U.S. patent application US20100183710A1
Wording in the published application’s summary of the invention, reproduced by Google Patents.
U.S. Food and Drug Administration
The records displayed here use the second-quarter snapshot, with a June 30, 2026 cutoff. The official page may offer a later quarterly list.
“A=active ; I=inactive”
U.S. Food and Drug Administration
FDA activity-status legend; the snapshot date applies to the records shown here.
U.S. Food and Drug Administration
FDA explains how DMFs support applications that reference their technical contents.
“Are neither approved nor disapproved.”
U.S. Food and Drug Administration
FDA statement about DMFs; active status is not product approval.
U.S. Food and Drug Administration
Type II covers drug substances, intermediates, preparation materials and drug products; a subject-level screen is needed to select API records.
“Type II Drug Substance, Drug Substance Intermediate, and Material Used in Their Preparation; or Drug Product”
U.S. Food and Drug Administration
FDA definition of Type II; the category is broader than API-only filings.
Center for Drug Evaluation, National Medical Products Administration
The October 5, 2026 snapshot contains the reported names, company fields and registration information used here.
“奥美拉唑”
Center for Drug Evaluation, National Medical Products Administration
Exact reported substance name selected from the supplied CDE snapshot; salt and enantiomer registrations are excluded.
Liaoning Medical Products Administration
Official explanation of the A and I identifiers, including the different routes by which a record can receive A status.
“未通过技术审评或尚未与制剂注册进行关联的标识为“I”。”
Liaoning Medical Products Administration
The regulator explains I as material that has not passed technical review or has not been linked to a formulation registration.
Compare Omeprazole registry names, statuses and chemical-form boundaries using the free samples. Subscribe to search, filter and export the complete available FDA and CDE records for your sourcing review.
Complete data requires an active subscription. Already subscribed? Sign in to access your data.
Report an Omeprazole data issue with the page address, registry number and supporting official source. APIRFQ support handles data corrections; contact the relevant company separately about material specifications or supply.
Contact data support